Business Context and Reporting Period
This Form 8-K Current Report for SeaStar Medical Holding Corp covers events occurring between June 17, 2025, and June 23, 2025. The Company, an emerging growth company focused on pediatric critical care (specifically its FDA-approved product QUELIMMUNE), reported the closing of a public equity offering, significant executive compensation reductions, and actions taken to regain compliance with Nasdaq listing requirements.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company completed a best efforts public offering on June 23, 2025, with expected net proceeds of approximately $3.39 million.
- Offering Details: The offering consisted of 4,935,385 shares of Common Stock, 1,218,462 Pre-Funded Warrants, and accompanying Series A and Series B Warrants. The combined offering price was $0.65 per unit.
- Liquidity Outlook: Management believes the net proceeds, combined with existing cash and cash equivalents, will fund planned operations through November 2025.
- Liability Reduction: Approximately $1.2 million in accrued employee compensation and Director fee liabilities were extinguished in May and June 2025 through waivers.
- Operating Expense Reduction: The Company expects to reduce monthly operating expenses by approximately $50,000 following a 20% salary reduction for the CEO, CFO, CMO, and other management, as well as a 20% reduction in Director retainers.
- Revenue: The filing does not provide specific revenue figures for the current period, noting only that customer count for QUELIMMUNE increased to six in the second fiscal quarter.
Material Changes and Corporate Actions
- Equity Offering: The Company entered into a Securities Purchase Agreement with institutional investors, closing the transaction on June 23, 2025. This includes a 60-day lock-up period on new issuances and a one-year restriction on variable rate transactions.
- Cost Cutting Measures: Effective June 17, 2025, the Board approved indefinite 20% salary reductions for key executives and Directors to reduce ongoing operating expenses.
- Nasdaq Compliance: The Company previously received notice of non-compliance with the $35 million Minimum Market Value of Listed Securities (MVLS) requirement. A Nasdaq Hearings Panel granted an exception until June 22, 2025, to demonstrate compliance with the $2.5 million stockholders' equity requirement. The Company asserts it is now in compliance based on the fundraising and liability restructuring actions.
- ATM Facility: On April 25, 2025, the Company entered into an agreement with Lincoln Park Capital to sell up to $15.0 million of Common Stock over time.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Net proceeds from the June 2025 offering will be used for general corporate purposes, including costs associated with being a public company.
- Operational Impact: Management does not anticipate that the expense reductions will have a material impact on operations.
- Risks: The filing highlights risks related to the volatility of the stock market, the research and development process, and the continued listing of common stock on the Nasdaq Capital Market. Forward-looking statements regarding operating expenses and liabilities are subject to uncertainties.
- Product Status: QUELIMMUNE is FDA-approved for treating pediatric patients with multiple organ failure, with claims of reducing pediatric mortality by approximately 50%.
Investor Verification Checklist
- Verify the actual cash balance and burn rate to confirm the runway extends through November 2025 as stated.
- Confirm the final closing statement of the June 23, 2025 offering to validate the $3.39 million net proceeds figure.
- Monitor the Company's stock price and market capitalization to ensure continued compliance with Nasdaq listing rules post-June 22, 2025.
- Review the terms of the Lincoln Park Capital ATM agreement to understand potential future dilution.
- Assess the impact of the 20% executive pay cuts on retention and operational stability.